TMCI StockTwits Mentions

The stock has rallied sharply, up 44.8% in the last month, but still trades below its 200-day moving average of $3.71 at $2.78. This pattern suggests a strong short-term rebound within a broader downtrend, leaving the technical picture mixed. The recent momentum is encouraging, but the longer-term trend remains cautious until the price can sustain above the 200-day average.

• Price at $2.78 remains below the 200-day moving average of $3.71, indicating the longer-term trend is still downward despite the recent bounce.
• A 44.8% one-month gain signals strong positive momentum and possible short-covering or renewed speculative interest.
• Without an RSI provided, the combination of sharp recent gains and a price still under the 200-day MA points to a recovery attempt that has not yet reversed the broader bearish technical structure.

Alternative data show modestly positive operational and brand signals, particularly in hiring and professional-network presence, but no explosive growth. Job openings are up month over month, and LinkedIn followers are growing, suggesting continued investment and awareness in the professional and medical community. Social channels are mostly stable to slightly positive, while web traffic appears relatively small, implying a niche but engaged footprint.

• Job openings at 19, up 11.8% MoM, indicate the company is still investing in growth and operations rather than retrenching, a mild positive for business outlook.
• LinkedIn followers at 42,055 with 1.8% growth in 90 days highlight a solid and gradually expanding professional presence, important for a medtech company selling into physicians and hospitals.
• Social media metrics are mixed but generally stable: small decline in Twitter/X followers (-1.6%) offset by slight growth on Instagram, Facebook, and flat YouTube, suggesting no major brand deterioration but also no viral inflection; web traffic at ~14,320 visitors/month looks modest, consistent with a specialized medical-device niche.

Treace Medical Concepts shows a speculative profile: strong recent share-price rebound and modestly positive alternative data signals, but underpinned by a currently unprofitable financial base. The stock appears to be in a recovery attempt within a longer-term downtrend, and sustained upside likely depends on evidence of improving earnings and margins. Overall, the balance of risk and opportunity is best characterized as neutral at this stage.

• Negative earnings and a price still below the 200-day moving average temper enthusiasm despite the sharp one-month rally.
• Hiring growth and a gradually expanding professional/social footprint are constructive, but not yet strong enough to offset the lack of profitability, leaving the outlook balanced rather than clearly bullish or bearish.